AI in Genomics Market (2022 to 2035)

AI in Genomics Market Summary:

The global AI in Genomics market size was valued at USD 1134.80 Million in 2025 and is projected to reach USD 20558.14 Million by 2035, expanding at a CAGR of 33.60% from 2026 to 2035. Market growth is supported by the increasing integration of artificial intelligence in genomic data analysis, the expanding adoption of precision medicine and personalized healthcare, and rising investments in large-scale genome sequencing and AI-driven drug discovery initiatives.

Years	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
Revenue (USD Mn)	475.88	XX	XX	1134.80	XX	XX	XX	XX	XX	XX	XX	XX	XX	20558.14

Key Market Takeaways & Insights

• North America AI in Genomics market held the largest share of 39.10% of the global market in 2025.
• The AI in Genomics industry in the Asia Pacific is expected to grow significantly over the forecast period.
• By Component, the Software segment held the largest market share of 58.70% in 2025.
• By Technology, the Machine Learning (ML) segment held the largest market share in 2025.
• By Functionality, the Genome Sequencing segment held the largest market share in 2025.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 AI in Genomics Market Size: USD 1134.80 Million
• 2035 AI in Genomics Market Size: USD 20558.14 Million

Region

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

North America

XX

XX

XX

443.70

XX

XX

XX

XX

XX

XX

XX

XX

XX

6808.47

Europe

XX

XX

XX

338.17

XX

XX

XX

XX

XX

XX

XX

XX

XX

5389.93

Asia Pacific

XX

XX

XX

273.48

XX

XX

XX

XX

XX

XX

XX

XX

XX

5748.21

Latin America

XX

XX

XX

37.44

XX

XX

XX

XX

XX

XX

XX

XX

XX

663.33

Middle East & Africa

XX

XX

XX

41.98

XX

XX

XX

XX

XX

XX

XX

XX

XX

705.59

• CAGR (2026-2035): 33.60%

Genomic Data Landscape Analysis:

• Genome Sequencing Volume Trends
• Growth In Genomic Database Repositories
• Population Genomics Adoption Assessment
• Regional Genomic Data Generation Analysis

AI Technology Adoption Overview:

• Machine Learning Implementation trends
• AI-Enabled Genomic Interpretation Analysis
• Predictive Analytics Adoption Assessment
• Emerging AI Platform Benchmarking

2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
Conservative	1134.80	XX	XX	XX	XX	XX	XX	XX	XX	XX	17814.64
Likely	1134.80	XX	XX	XX	XX	XX	XX	XX	XX	XX	20558.14
Optimistic	1134.80	XX	XX	XX	XX	XX	XX	XX	XX	XX	27213.64

Market Dynamics:
Market Drivers:

Expanding Large-Scale Genomic Sequencing Programs and Population Biobanks

The rapid expansion of national genome, sequencing initiatives and large-scale biobank programs is generating unprecedented volumes of genomic data, creating a strong demand for artificial intelligence-powered analytics platforms. AI has become essential for processing, interpreting, and extracting clinically relevant insights from increasingly complex genomic datasets. The growth of population-scale genomics projects is significantly accelerating the adoption of machine learning algorithms for variant detection, disease prediction, biomarker identification, and precision medicine applications.

The evidence supporting this trend is substantial. The U.S. National Institutes of Health (NIH) All of Us Research Program reported that its genomic dataset expanded to more than 414,000 whole-genome sequences in 2025, representing nearly 70% growth in genomic data availability. Similarly, the UK Biobank has released whole-genome sequencing data for approximately 500,000 participants, making it one of the world's largest genomic resources for research and AI-driven discoveries.

These massive genomic repositories require advanced AI and machine learning tools to transform raw sequencing data into actionable insights for healthcare providers, pharmaceutical companies, and researchers. As governments and research organizations continue investing in national genomics infrastructure, the need for AI-enabled genomic interpretation platforms is expected to rise substantially, supporting long-term market growth. (Source: UK Biobank Limited, National Institutes of Health)

Rising Government and Research Investments in AI-Enabled Precision Medicine

Increasing government support for precision medicine and AI-enabled biomedical research is significantly driving the adoption of artificial intelligence in genomics. Public-sector organizations are investing heavily in genomic infrastructure, data-sharing frameworks, and AI-ready datasets to accelerate healthcare innovation. The U.S. National Institutes of Health (NIH) has established programs such as the Bridge2AI initiative, which focuses on developing standardized, AI-ready biomedical datasets that can be used to improve disease prediction, genomic analysis, and clinical decision-making.

Furthermore, the National Human Genome Research Institute (NHGRI) has highlighted artificial intelligence and machine learning as critical technologies for advancing genomic research and translating genomic discoveries into clinical applications. AI algorithms are increasingly being used to identify genetic mutations, discover biomarkers, optimize drug target identification, and support personalized treatment strategies.

The growing emphasis on precision medicine is encouraging collaborations among research institutions, healthcare providers, biotechnology firms, and government agencies, leading to accelerated deployment of AI-powered genomics platforms. These investments are not only improving the accessibility of genomic data but are also enhancing the ability of researchers to generate actionable insights from complex biological datasets. As governments continue prioritizing genomic medicine and digital health transformation, AI adoption across genomics research and clinical applications is expected to expand substantially, creating long-term growth opportunities for the market. (Source: National Institutes of Health)

Market Restraint:

Data Privacy, Security Risks, and Regulatory Compliance Challenges

The growing use of artificial intelligence in genomics requires access to massive volumes of highly sensitive genetic information, creating significant concerns regarding data privacy, cybersecurity, and regulatory compliance. Unlike traditional healthcare records, genomic data is permanent, uniquely identifiable, and can reveal information about individuals as well as their biological relatives. High-profile breaches have heightened concerns among healthcare providers, researchers, and patients regarding the security of genomic databases.

In 2023, the genetic testing company 23andMe experienced a major cyberattack that exposed the personal and genetic information of approximately 6.9 million customers globally, demonstrating the vulnerability of large genomic repositories to cyber threats. Furthermore, healthcare remains one of the most targeted sectors for cybercrime, accounting for approximately 43.38% of all reported data breaches across industries, according to published healthcare cybersecurity research. Regulatory frameworks such as HIPAA in the United States, GDPR in Europe, and various national genetic privacy laws impose stringent requirements on genomic data collection, storage, sharing, and AI model training.

These compliance obligations increase operational complexity and implementation costs for AI-driven genomics solutions. Concerns regarding unauthorized access, data misuse, cross-border data transfers, and algorithm transparency continue to slow the adoption of AI technologies in genomics research and clinical applications, making data governance one of the most significant barriers to market expansion. (Source: MDPI)

Shortage of Skilled Bioinformatics and Genomic Data Science Professionals

The successful deployment of artificial intelligence in genomics requires a highly specialized workforce with expertise spanning genomics, bioinformatics, computational biology, machine learning, and clinical research. However, the availability of professionals possessing these interdisciplinary skills remains limited across many regions. The rapid growth of sequencing technologies and AI-driven genomics applications has created demand that significantly exceeds the current talent supply. According to industry surveys, 96% of biopharma executives believe talent shortages will persist, citing continued difficulty in recruiting professionals with advanced computational and genomic expertise.

Additionally, reports from the genomics sector indicate that more than 70% of genomics-focused SMEs experience challenges in hiring specialists with data science and computational biology skills. Workforce shortages are particularly evident in clinical bioinformatics, genomic data interpretation, genetic counseling, and AI model development. The lack of qualified personnel can delay genomic research projects, increase implementation costs, slow technology adoption, and limit the scalability of AI-powered genomics platforms. As genomic datasets continue to expand and precision medicine initiatives gain momentum, addressing workforce development challenges through specialized education, training programs, and industry-academic partnerships will become critical for sustaining long-term market growth. (Sources: Biopharma Talent Shortage Survey, Workforce Development in Genomic Data Science (Researchgate.net))

Market Opportunities:

Expansion of AI-Powered Multi-Omics Platforms for Precision Medicine

The integration of artificial intelligence with multi-omics technologies represents one of the most significant growth opportunities in the AI in Genomics market. While genomics provides valuable insights into genetic variation, combining genomic data with transcriptomics, proteomics, metabolomics, and epigenomics enables a more comprehensive understanding of disease mechanisms and patient responses to treatment. The volume of biological data generated through multi-omics studies has grown substantially, creating a strong need for advanced AI and machine learning tools capable of identifying complex biological relationships. According to the U.S. National Institutes of Health (NIH), the All of Us Research Program has enrolled more than 850,000 participants and collected over 650,000 whole genome sequences, creating one of the largest and most diverse biomedical datasets available for AI-driven precision medicine research.

Additionally, the program continues to integrate genomic, lifestyle, environmental, and clinical data to support the development of personalized healthcare solutions. AI-powered multi-omics platforms are increasingly being used to identify novel biomarkers, predict disease progression, optimize treatment selection, and accelerate drug discovery. Pharmaceutical and biotechnology companies are also expanding investments in multi-omics research to improve therapeutic success rates and reduce development timelines. As healthcare systems shift toward individualized patient care and preventive medicine, the demand for AI-enabled platforms capable of integrating and interpreting diverse biological datasets is expected to increase significantly. This trend positions multi-omics analytics as a major long-term opportunity for technology providers, healthcare organizations, and life sciences companies operating in the AI in Genomics market. (Source: National Institutes of Health, National Human Genome Research Institute (NHGRI))

By Component	2025
Software	58.70%
Hardware	24.60%
Service	16.70%

AI In Genomics Market Segmentations Analysis:

By Component (Software, Hardware, Service)

The Software segment accounted for the largest share of the AI in Genomics market due to its critical role in genomic data analysis, variant interpretation, predictive modeling, and precision medicine workflows. The increasing adoption of AI-powered bioinformatics platforms, cloud-based genomic analytics solutions, and machine learning algorithms by research institutions, healthcare providers, and pharmaceutical companies continues to strengthen the segment's market leadership.

The Services segment is projected to witness the fastest growth during the forecast period, driven by the rising demand for AI implementation, genomic data management, consulting, model training, and bioinformatics support services. Growing outsourcing activities among biotechnology and pharmaceutical companies, coupled with the increasing complexity of genomic datasets, are accelerating demand for specialized AI and genomics expertise.

By Technology (Machine Learning (ML), (Deep Learning, Supervised Learning, Unsupervised Learning, and Others), Computer Vision)

The Machine Learning (ML) segment held the largest share of the AI in Genomics market owing to its extensive application in genomic sequencing analysis, disease risk prediction, biomarker discovery, and drug target identification. ML algorithms enable the efficient processing of vast genomic datasets, helping researchers and healthcare providers derive actionable insights and advance precision medicine initiatives across clinical and research settings.

The Computer Vision segment is expected to register the fastest growth during the forecast period, driven by its increasing use in genomic imaging, digital pathology, and cellular analysis applications. The integration of computer vision with AI-powered diagnostic platforms is improving the interpretation of complex biological images, supporting disease detection, phenotype characterization, and translational research in genomics and precision healthcare.

By Functionality (Genome Sequencing, Gene Editing, Others)

The Genome Sequencing segment accounted for the largest share of the AI in Genomics market due to the widespread adoption of next-generation sequencing (NGS) technologies and large-scale genome mapping initiatives. AI is increasingly utilized to accelerate sequence analysis, identify genetic variants, and interpret complex genomic datasets, supporting applications in precision medicine, disease diagnosis, and pharmaceutical research.

The Gene Editing segment is projected to be the fastest-growing segment during the forecast period, driven by advancements in CRISPR and other genome engineering technologies. AI is enhancing gene-editing workflows by improving target identification, predicting off-target effects, and optimizing editing efficiency, thereby accelerating research activities and the development of next-generation genetic therapies.

By Application (Drug Discovery & Development, Precision Medicine, Diagnostics, Other Applications)

The Drug Discovery & Development segment held the largest share of the AI in Genomics market owing to the increasing use of AI for target identification, biomarker discovery, lead optimization, and clinical research. Pharmaceutical and biotechnology companies are leveraging AI-driven genomic insights to accelerate drug development timelines, reduce research costs, and improve the probability of therapeutic success across multiple disease areas.

The Precision Medicine segment is expected to witness the fastest growth during the forecast period, driven by the growing emphasis on personalized healthcare and genomics-based treatment strategies. AI technologies enable the analysis of complex genetic and clinical datasets to support patient stratification, disease risk prediction, and individualized therapy selection, enhancing treatment outcomes and healthcare efficiency.

By End Use (Pharmaceutical and Biotech Companies, Healthcare Providers, Research Centers, Others)

The Pharmaceutical and Biotech Companies segment accounted for the largest share of the AI in Genomics market due to extensive investments in AI-driven drug discovery, biomarker identification, and genomic research. These organizations leverage advanced AI platforms to analyze large-scale genomic datasets, accelerate therapeutic development, optimize clinical trials, and improve the efficiency of precision medicine programs.

The Healthcare Providers segment is projected to register the fastest growth during the forecast period, driven by the increasing integration of genomics into routine clinical practice and personalized patient care. Hospitals, diagnostic laboratories, and healthcare networks are adopting AI-powered genomic tools to enhance disease diagnosis, treatment planning, risk assessment, and precision medicine delivery, supporting improved patient outcomes.

AI In Genomics Market Regional Insights:

By Geography	2022	2025	2035
North America	XX	443.70	XX
US	XX	410.87	XX
Canada	XX	32.83	XX
Europe	XX	338.17	XX
Germany	XX	69.32	XX
UK	XX	43.28	XX
France	XX	52.75	XX
Italy	XX	29.08	XX
Spain	XX	27.72	XX
Switzerland	XX	10.48	XX
Netherlands	XX	7.10	XX
Rest of Europe	XX	98.4	XX
Asia Pacific	XX	273.48	XX
China	XX	114.59	XX
India	XX	20.78	XX
Japan	XX	43.21	XX
South Korea	XX	39.10	XX
Singapore	XX	9.84	XX
Australia	XX	14.22	XX
Thailand	XX	3.55	XX
Malaysia	XX	6.83	XX
Philippines	XX	5.46	XX
Indonesia	XX	4.37	XX
Rest of Asia Pacific	XX	11.48	XX
Middle East & Africa	XX	41.98	XX
Saudi Arabia	XX	13.77	XX
United Arab Emirates	XX	10.87	XX
South Africa	XX	6.34	XX
Egypt	XX	3.44	XX
Israel	XX	4.53	XX
Rest of MEA	XX	13.77	XX
Latin America	XX	37.44	XX
Brazil	XX	12.32	XX
Mexico	XX	8.80	XX
Argentina	XX	3.96	XX
Chile	XX	3.22	XX
Colombia	XX	1.94	XX
Peru	XX	1.61	XX
Rest of LA	XX	5.57	XX

North America AI In Genomics Market Analysis:

North America AI in Genomics market held the largest share of 39.10% of the global market in 2025 and was valued at approximately USD 443.70 Million. The regional market is primarily driven by the presence of advanced genomics research infrastructure, substantial investments in artificial intelligence and precision medicine, strong government support for large-scale genome sequencing programs, and the growing adoption of AI-powered drug discovery and clinical genomics solutions.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 AI In Genomics Market Size: USD 443.70 Million
• 2035 AI In Genomics Market Size: USD 6808.47 Million
• AI In Genomics Market CAGR (2026-2033): 31.40%

Drivers

• Widespread Adoption of Precision Medicine Programs
• Strong Presence of AI and Genomics Industry Leaders
• Expansion of Large-Scale Genomic Sequencing Projects
• Increasing Investments in AI-Driven Drug Discovery

Restraints

• Stringent Data Privacy and Patient Consent Requirements
• High Cost of AI Infrastructure and Genomic Analysis
• Interoperability Challenges Across Healthcare Systems
• Shortage of Multidisciplinary AI-Genomics Talent

Opportunities

• Integration of Multi-Omics Analytics Platforms
• Expansion of AI-Based Predictive Healthcare Models

United State AI In Genomics Market Analysis:

The U.S. accounted for the dominant share within North America and represented approximately 92.60% of the regional market in 2025. The country market is supported by extensive genomic research activities, increasing investments from pharmaceutical and biotechnology companies, widespread implementation of AI-driven healthcare technologies, and the availability of large genomic databases that facilitate precision medicine development.

Drivers

• Large-Scale Precision Medicine Initiatives
• Expansion of AI-Driven Drug Discovery Programs
• Strong Genomic Data Infrastructure
• Growing Investment from Biopharma Companies

Restraints

• Stringent Patient Data Privacy Regulations
• High Computational Infrastructure Costs
• Genomic Data Standardization Challenges
• Shortage of AI-Genomics Specialists

Opportunities

• AI Integration in Population-Scale Genomic Screening
• Development of Multi-Omics AI Platforms

Canada AI In Genomics Market Analysis:

Canada represented approximately 7.40% of the North American market in 2025 and was valued at around USD 32.83 Million. The market is driven by government-backed genomics initiatives, growing adoption of AI in healthcare research, increasing collaboration between academic institutions and biotechnology companies, and rising demand for personalized healthcare solutions.

Drivers

• National Genome Sequencing Programs
• Government Support for AI Research Ecosystems
• Rising Adoption of Personalized Healthcare
• Expansion of Academic Genomics Collaborations

Restraints

• Limited Commercialization of Research Outputs
• Smaller Genomic Datasets Compared to USA
• Dependence on External AI Technology Providers
• Healthcare Budget Constraints

Opportunities

• Indigenous Population Genomics Programs
• AI-Powered Rare Disease Diagnostics

Europe AI In Genomics Market Analysis:

Europe accounted for approximately 29.8% of the global AI in Genomics market in 2025 and was valued at nearly USD 338.17 Million. The regional market is primarily fueled by strong public funding for genomics research, expanding precision medicine programs, increasing integration of artificial intelligence into healthcare systems, and growing collaborations among research institutes, healthcare providers, and biotechnology companies.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 AI In Genomics Market Size: USD 338.17 Million
• 2035 AI In Genomics Market Size: USD 5389.93 Million
• AI In Genomics Market CAGR (2026-2033): 31.90%

Drivers

• Government-Supported Genomics Research Initiatives
• Growing Adoption of Personalized Healthcare Solutions
• Increasing Collaboration Between Academia and Industry
• Rising Investments in Digital Health Transformation

Restraints

• Complex Regulatory and GDPR Compliance Requirements
• Fragmented Healthcare Data Ecosystems
• Limited Cross-Border Genomic Data Accessibility
• Lengthy Clinical Validation Processes for AI Tools

Opportunities

• Development of Federated Genomic Data Networks
• AI-Powered Rare Disease and Oncology Research

United KingdomAI In Genomics Market Analysis

The UK represented approximately 12.80% of the European market in 2025 and was valued at nearly USD 43.28 Million. Growth is supported by national genomics initiatives, extensive genomic data resources, increasing adoption of AI-enabled healthcare technologies, and continued investments in precision medicine and biomedical research programs.

Drivers

• Leadership in Genomic Medicine Programs
• NHS Genomics Integration Initiatives
• Expansion of AI HealthTech Startups
• National Genome Database Accessibility

Restraints

• Post-Brexit Regulatory Uncertainty
• Clinical Adoption Barriers
• Limited Skilled Genomic Data Scientists
• Cybersecurity Risks in Health Data

Opportunities

• AI-Enabled Preventive Genomics
• Expansion of Federated Genomic Data Platforms

GermanyAI In Genomics Market Analysis

Germany accounted for approximately 20.50% of the European market in 2025 and was valued at around USD 69.32 Million. The market benefits from a robust biotechnology sector, increasing investments in digital health and genomics research, strong academic-industry partnerships, and rising adoption of AI-based genomic analysis tools in clinical and research applications.

Drivers

• Strong Biotechnology Sector Growth
• Advanced Bioinformatics Research Network
• AI Adoption in Clinical Genomics
• Government Funding for Digital Health

Restraints

• GDPR Compliance Complexity
• Fragmented Healthcare Data Systems
• Limited Cross-Border Data Sharing
• High Validation Requirements for AI Models

Opportunities

• AI-Based Cancer Genomics Expansion
• Precision Therapeutics Development

France AI In Genomics Market Analysis

The France represented approximately 15.60% of the European market in 2025 and was valued at nearly USD 52.75 Million. The market is driven by growing investments in artificial intelligence research, expanding precision healthcare initiatives, increasing genomic testing adoption, and strong government support for digital healthcare transformation.

Drivers

• National Investments in Health AI
• Growth in Genomic Research Consortia
• Increasing Precision Oncology Projects
• Public-Private Genomics Partnerships

Restraints

• Data Access Restrictions
• Slow Technology Procurement Processes
• Limited AI Commercial Deployment
• Reimbursement Challenges

Opportunities

• AI-Based Biomarker Discovery
• Genomic Applications in Rare Diseases

Italy AI In Genomics Market Analysis

Italy accounted for approximately 8.60% of the European market in 2025 and was valued at around USD 29.08 Million. The country market is supported by rising demand for personalized medicine, increasing genomic research activities, expanding healthcare digitization efforts, and growing utilization of AI-powered diagnostic and analytical platforms.

Drivers

• Rising Demand for Precision Diagnostics
• Increased Academic Genomics Research
• Growing AI Healthcare Investments
• Expansion of Genomic Testing Services

Restraints

• Regional Healthcare Inequalities
• Limited AI Infrastructure Deployment
• Fragmented Genomic Databases
• Lack of Specialized Talent

Opportunities

• AI-Assisted Hereditary Disease Screening
• Genomics Expansion in Public Healthcare

SpainAI In Genomics Market Analysis

The Spain represented approximately 8.20% of the European market in 2025 and was valued at nearly USD 27.72 Million. Growth is fueled by expanding genomics research programs, increasing healthcare digitalization, rising investments in precision medicine, and growing adoption of advanced bioinformatics and AI technologies.

Drivers

• National Digital Health Transformation Programs
• Increasing Clinical Genomics Adoption
• Growth in Bioinformatics Capabilities
• Expansion of Precision Medicine Networks

Restraints

• Budget Limitations in Healthcare Systems
• Insufficient Genomic Workforce
• Data Integration Difficulties
• Slow Regulatory Approvals

Opportunities

• AI-Powered Population Genomics Studies
• Drug Response Prediction Platforms

Switzerland AI In Genomics Market Analysis

Switzerland accounted for approximately 3.10% of the European market in 2025 and was valued at around USD 10.48 Million. The market benefits from a strong pharmaceutical industry presence, advanced life sciences research capabilities, growing investments in AI-driven drug development, and increasing demand for precision healthcare solutions.

Drivers

• Strong Pharmaceutical R&D Ecosystem
• Advanced Life Sciences Innovation
• High Genomic Research Investments
• AI Adoption in Drug Development

Restraints

• High Operating Costs
• Data Protection Compliance Burden
• Talent Competition Across Industries
• Small Domestic Population Base

Opportunities

• AI-Driven Companion Diagnostics
• Cross-Border Genomic Collaboration Programs

Netherlands AI In Genomics Market Analysis

Netherlands represented approximately 2.10% of the European market in 2025 and was valued at nearly USD 7.10 Million. The country market is driven by advanced healthcare infrastructure, strong genomics research capabilities, increasing adoption of AI-based healthcare technologies, and growing public-private collaborations in precision medicine.

Drivers

• Robust Digital Healthcare Infrastructure
• Growth in Translational Genomics Research
• Government Support for AI Innovation
• Strong Academic-Industry Collaboration

Restraints

• Limited Availability of Longitudinal Data
• High AI Implementation Costs
• Interoperability Issues Across Institutions
• Regulatory Complexity

Opportunities

• AI-Based Preventive Healthcare Models
• Real-World Genomic Evidence Platforms

Asia Pacific AI In Genomics Market Analysis

Asia-Pacific accounted for approximately 24.10% of the global market in 2025 and was valued at nearly USD 273.48 Million. The regional market is primarily driven by expanding genome sequencing initiatives, increasing government investments in artificial intelligence and biotechnology, growing healthcare digitization, and rising demand for precision medicine across both developed and emerging economies.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 AI In Genomics Market Size: USD 273.48 Million
• 2035 AI In Genomics Market Size: USD 5748.21 Million
• AI In Genomics Market CAGR (2026-2033): 35.60%

Drivers

• Rapid Expansion of National Genome Mapping Programs
• Growing Government Support for Artificial Intelligence Innovation
• Rising Healthcare Digitization Across Emerging Economies
• Increasing Demand for Precision Medicine and Diagnostics

Restraints

• Uneven Healthcare Infrastructure Development
• Limited Availability of Skilled Bioinformatics Professionals
• Data Standardization and Quality Challenges
• Regulatory Variability Across Countries

Opportunities

• Large Untapped Population Genomics Datasets
• Expansion of Affordable AI-Enabled Genetic Testing Services

China AI In Genomics Market Analysis

China represented approximately 41.90 % of the Asia-Pacific market in 2025 and was valued at around USD 114.59 Million. The market is supported by large-scale genomic data generation, strong government backing for AI innovation, expanding biotechnology research activities, and increasing adoption of precision medicine across healthcare institutions.

Drivers

• Massive Genomic Data Generation Capacity
• Government-Led AI Development Strategies
• Rapid Expansion of Precision Medicine Programs
• Strong Domestic Sequencing Industry

Restraints

• Data Localization Requirements
• Limited International Data Sharing
• Regulatory Evolution Uncertainty
• Regional Healthcare Disparities

Opportunities

• AI-Based Population Health Genomics
• Genomic Drug Target Identification

India AI In Genomics Market Analysis:

India accounted for approximately 7.60% of the Asia-Pacific market in 2025 and was valued at nearly USD 20.78 Million. Growth is fueled by national genome sequencing initiatives, expanding healthcare infrastructure, increasing investments in AI-based healthcare technologies, and growing awareness of genomics-driven personalized medicine.

Drivers

• Expanding National Genome Projects
• Rising AI Healthcare Startup Activity
• Growing Demand for Precision Medicine
• Increasing Genomics Research Funding

Restraints

• Limited Genomic Awareness Among Clinicians
• Data Quality Variability
• Shortage of Skilled Bioinformaticians
• Infrastructure Gaps in Rural Regions

Opportunities

• Affordable AI-Driven Genetic Testing
• Genomics Applications in Disease Prevention

Japan AI In Genomics Market Analysis

Japan represented approximately 15.80% of the Asia-Pacific market in 2025 and was valued at around USD 43.21 Million. The country market benefits from advanced healthcare technologies, strong genomic research capabilities, increasing adoption of AI in drug discovery, and rising demand for personalized treatment approaches among an aging population.

Drivers

• Advanced Healthcare Technology Ecosystem
• Growing Adoption of Precision Oncology
• Strong Genomic Research Institutions
• Aging Population Driving Personalized Medicine

Restraints

• Conservative Clinical Adoption Practices
• High Compliance Standards
• Limited Data Interoperability
• Workforce Constraints

Opportunities

• AI for Age-Related Disease Genomics
• Multi-Omics Research Expansion

South Korea AI In Genomics Market Analysis

South Korea represented approximately 14.30% of the Asia-Pacific market in 2025 and was valued at around USD 39.10 Million. The market is driven by government-led digital healthcare initiatives, expanding genomic research programs, strong AI innovation ecosystems, and increasing use of precision medicine technologies.

Drivers

• Government Support for AI Healthcare Innovation
• Expansion of Genomic Data Repositories
• Strong Digital Healthcare Infrastructure
• Rapid AI Commercialization Activities

Restraints

• Regulatory Approval Delays
• Dependence on Imported Genomic Technologies
• Data Privacy Concerns
• Limited Global Data Integration

Opportunities

• AI-Enabled Precision Oncology Programs
• Genomics Applications in Preventive Care

Singapore AI In Genomics Market Analysis:

Singapore accounted for approximately 3.60 % of the Asia-Pacific market in 2025 and was valued at nearly USD 9.84 Million. Growth is supported by world-class biomedical research infrastructure, strong government investments in artificial intelligence, expanding precision medicine programs, and increasing international genomics collaborations.

Drivers

• National AI Strategy Implementation
• World-Class Biomedical Research Ecosystem
• Strong Precision Medicine Programs
• International Research Collaborations

Restraints

• Small Population Data Pool
• Talent Acquisition Challenges
• High Technology Deployment Costs
• Limited Domestic Market Size

Opportunities

• Regional Genomics Data Hub Development
• AI-Based Clinical Decision Support

Australia AI In Genomics Market Analysis

Australia represented approximately 5.20 % of the Asia-Pacific market in 2025 and was valued at around USD 14.22 Million. The market benefits from national genomics health initiatives, increasing investments in healthcare innovation, growing adoption of AI-enabled clinical genomics, and strong academic research capabilities.

Drivers

• National Genomics Health Programs
• Increasing AI Research Investments
• Expansion of Precision Healthcare Services
• Strong Academic Research Base

Restraints

• Geographic Healthcare Access Gaps
• Limited Commercial Genomics Scale
• Data Governance Challenges
• Skilled Workforce Shortages

Opportunities

• Indigenous Genomics Research Initiatives
• AI-Driven Rare Disease Programs

Thailand AI In Genomics Market Analysis

Thailand represented approximately 1.30 % of the Asia-Pacific market in 2025 and was valued at around USD 3.55 Million. The country market is driven by healthcare modernization efforts, increasing genomic testing adoption, growing digital health investments, and rising interest in precision medicine applications.

Drivers

• Government Focus on Digital Healthcare
• Rising Genomic Testing Adoption
• Expansion of Medical Research Institutes
• Growing Healthcare Modernization Efforts

Restraints

• Limited Funding for Advanced Genomics
• Lack of Genomic Specialists
• Data Infrastructure Constraints
• Technology Adoption Barriers

Opportunities

• Precision Medicine Expansion Programs
• AI-Enabled Infectious Disease Genomics

Malaysia AI In Genomics Market Analysis:

Malaysia accounted for approximately 2.50 % of the Asia-Pacific market in 2025 and was valued at nearly USD 6.83 Million. Growth is supported by expanding biotechnology activities, increasing healthcare digitization, growing government support for AI innovation, and rising investments in genomics research.

Drivers

• Growth of Biotechnology Industry
• Increasing Healthcare Digitization
• Rising Genomic Research Activities
• Government Support for AI Innovation

Restraints

• Limited Local Genomic Databases
• Shortage of AI Healthcare Talent
• Budget Constraints
• Low Clinical Adoption Rates

Opportunities

• AI-Based Personalized Healthcare Services
• Regional Genomics Research Partnerships

Philippines AI In Genomics Market Analysis

Philippines represented approximately 2.00 % of the Asia-Pacific market in 2025 and was valued at around USD 5.46 Million. The market is fueled by improving healthcare infrastructure, increasing adoption of digital health technologies, growing research collaborations, and rising awareness of genomic medicine.

Drivers

• Expanding Healthcare Modernization Initiatives
• Growing Interest in Precision Medicine
• Increased Research Collaborations
• Emerging Digital Health Ecosystem

Restraints

• Limited Sequencing Infrastructure
• Funding Constraints
• Lack of Specialized Workforce
• Fragmented Health Data Systems

Opportunities

• AI Applications in Public Health Genomics
• Genetic Disease Screening Expansion

Indonesia AI In Genomics Market Analysis

Indonesia represented approximately 1.60 % of the Asia-Pacific market in 2025 and was valued at around USD 4.37 Million. The country market benefits from a large patient population, expanding healthcare investments, growing government focus on digital transformation, and increasing adoption of AI-driven healthcare solutions.

Drivers

• Large Population Supporting Genomic Research
• Rising Government Healthcare Investments
• Expansion of AI Innovation Programs
• Increasing Disease Surveillance Initiatives

Restraints

• Limited Genomics Infrastructure
• Uneven Healthcare Accessibility
• Data Collection Challenges
• Talent Scarcity

Opportunities

• Population-Wide Genomic Studies
• AI-Based Infectious Disease Monitoring

Middle East & AfricaAI In Genomics Market Analysis

Middle East & Africa accounted for approximately 3.70 % of the global market in 2025 and was valued at nearly USD 41.98 Million. The regional market is primarily driven by healthcare modernization programs, increasing investments in biotechnology and artificial intelligence, expanding genomics research initiatives, and growing interest in precision medicine and preventive healthcare.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 AI In Genomics Market Size: USD 41.98 Million
• 2035 AI In Genomics Market Size: USD 705.59 Million
• AI In Genomics Market CAGR (2026-2033): 32.60%

Drivers

• National Healthcare Modernization Strategies
• Growing Investments in Biotechnology and AI Ecosystems
• Expansion of Genomics Research Programs
• Rising Focus on Preventive and Personalized Medicine

Restraints

• Limited Genomics Infrastructure in Developing Economies
• Dependence on Imported Technologies and Expertise
• Insufficient Genomic Data Repositories
• Limited Availability of Specialized Workforce

Opportunities

• Establishment of Regional Genomics Centers of Excellence
• AI-Based Screening for Genetic and Inherited Disorders

Saudi Arabia AI In Genomics Market Analysis:

Saudi Arabia accounted for approximately 32.80% of the Middle East market in 2025 and was valued at nearly USD 13.77 Million. The market is supported by Vision 2030 healthcare transformation initiatives, expanding national genome programs, increasing investments in AI technologies, and growing adoption of personalized healthcare solutions.

Drivers

• Vision 2030 Healthcare Transformation
• National Genome Program Expansion
• Growing AI Investments
• Increasing Precision Medicine Initiatives

Restraints

• Dependence on Foreign Technology Providers
• Limited Skilled Workforce
• Data Governance Challenges
• Early-Stage Clinical Adoption

Opportunities

• AI-Based Genetic Disease Management
• Regional Genomics Leadership Development

United Arab Emirates AI In Genomics Market Analysis

United Arab Emirates represented approximately 25.90 % of the Middle East market in 2025 and was valued at around USD 10.87 Million. Growth is fueled by strong government support for artificial intelligence, increasing healthcare innovation investments, expanding genomics infrastructure, and rising adoption of precision medicine programs.

Drivers

• National AI Strategy Deployment
• Investments in Genomics Infrastructure
• Expansion of Precision Healthcare Services
• Growing HealthTech Ecosystem

Restraints

• Limited Native Genomic Datasets
• Talent Availability Constraints
• Data Privacy Compliance Requirements
• Small Population Size

Opportunities

• Genomics Innovation Hubs
• AI-Powered Preventive Medicine Programs

South Africa AI In Genomics Market Analysis

South Africa represented approximately 15.10 % of the Middle East market in 2025 and was valued at around USD 6.34 Million. The country market benefits from growing genomics research activities, increasing international collaborations, expanding disease surveillance programs, and rising demand for advanced diagnostic technologies.

Drivers

• Rising Genomic Research Activities
• Growing Disease Surveillance Programs
• Increasing International Collaborations
• Expansion of Precision Diagnostics

Restraints

• Healthcare Funding Limitations
• Unequal Access to Advanced Healthcare
• Infrastructure Gaps
• Limited Sequencing Capacity

Opportunities

• African Population Genomics Studies
• AI-Based Infectious Disease Research

Egypt AI In Genomics Market Analysis:

Egypt accounted for approximately 8.20 % of the Middle East & Africa market in 2025 and was valued at nearly USD 3.44 Million. The market is driven by healthcare digitization efforts, increasing investments in medical research, expanding genomic testing capabilities, and growing adoption of AI-powered healthcare solutions.

Drivers

• Healthcare Digitization Initiatives
• Growth of Medical Research Programs
• Increasing Government Health Investments
• Rising Adoption of Genomic Testing

Restraints

• Budget Constraints
• Limited Bioinformatics Expertise
• Regulatory Development Challenges
• Data Integration Issues

Opportunities

• Precision Medicine Expansion
• AI-Based Population Health Programs

Israel AI In Genomics Market Analysis

Israel represented approximately 7.20 % of the Middle East and Africa market in 2025 and was valued at around USD 3.02 Million. Growth is supported by a highly developed biotechnology ecosystem, strong AI innovation capabilities, increasing genomics research investments, and extensive collaboration between academia and industry.

Drivers

• Strong AI Innovation Ecosystem
• Advanced Biotechnology Sector
• Robust Genomics Research Infrastructure
• High Venture Capital Activity

Restraints

• Data Sharing Restrictions
• Talent Competition
• Small Domestic Market
• Regulatory Complexity

Opportunities

• AI-Driven Drug Discovery Expansion
• Global Genomics Partnerships

Latin AmericaAI In Genomics Market Analysis

Latin America accounted for approximately 3.30% of the global market in 2025 and was valued at around USD 37.44 Million. The regional market is primarily fueled by increasing investments in healthcare modernization, growing adoption of precision medicine, expanding genomics research activities, and rising integration of artificial intelligence into healthcare systems.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 AI In Genomics Market Size: USD 37.44 Million
• 2035 AI In Genomics Market Size: USD 663.33 Million
• AI In Genomics Market CAGR (2026-2033): 33.30 %

Drivers

• Increasing Adoption of Precision Healthcare Initiatives
• Growth in Public and Private Genomics Research Investments
• Rising Demand for Personalized Disease Management
• Expansion of Digital Health Infrastructure

Restraints

• Economic and Healthcare Funding Constraints
• Limited Access to Advanced Sequencing Technologies
• Shortage of AI and Genomics Specialists
• Fragmented Health Data Management Systems

Opportunities

• Population-Based Genomic Research Programs
• AI-Driven Disease Risk Assessment and Early Diagnosis Solutions

Brazil AI In Genomics Market Analysis:

Brazil accounted for approximately 32.90 % of the Latin America market in 2025 and was valued at nearly USD 12.32 Million. The market is supported by strong biomedical research activities, increasing adoption of genomic diagnostics, growing investments in AI-enabled healthcare technologies, and expanding precision medicine initiatives.

Drivers

• Expanding Precision Medicine Programs
• Growth in Genomic Research Institutions
• Rising AI Healthcare Investments
• Large Population Health Databases

Restraints

• Economic Volatility
• Limited Genomics Infrastructure Outside Major Cities
• Regulatory Uncertainty
• Workforce Skill Gaps

Opportunities

• Population-Scale Genomic Research
• AI-Based Oncology Diagnostics

Mexico AI In Genomics Market Analysis:

Mexico accounted for approximately 23.50 % of the Latin America market in 2025 and was valued at nearly USD 8.80 Million. Growth is driven by healthcare digitalization efforts, increasing demand for personalized medicine, expanding genomics research collaborations, and rising adoption of advanced diagnostic technologies.

Drivers

• Increasing Adoption of Genomic Diagnostics
• Government Healthcare Modernization Efforts
• Growing Academic Research Collaborations
• Rising Demand for Personalized Medicine

Restraints

• Funding Constraints
• Limited Access to Advanced Sequencing
• Data Management Challenges
• Shortage of Specialists

Opportunities

• Precision Healthcare Expansion
• AI-Based Rare Disease Detection

Argentina AI In Genomics Market Analysis

Argentina represented approximately 10.60 % of the Latin America market in 2025 and was valued at around USD 3.96 Million. The country market benefits from a well-established biomedical research sector, growing interest in AI-driven healthcare applications, increasing genomics research activities, and expanding international partnerships.

Drivers

• Strong Biomedical Research Capabilities
• Growing Interest in AI Healthcare Applications
• Expansion of Genomics Research Projects
• Increasing International Collaborations

Restraints

• Economic Instability
• Limited Private Investments
• Technology Adoption Delays
• Regulatory Barriers

Opportunities

• AI-Powered Clinical Genomics
• Expansion of Translational Research Programs

Chile AI In Genomics Market Analysis

Chile represented approximately 8.60 % of the Latin America market in 2025 and was valued at around USD 3.22 Million. The market is supported by national digital health initiatives, increasing precision medicine awareness, growing healthcare innovation investments, and expanding research collaborations in genomics.

Drivers

• National Digital Health Development Programs
• Increasing Precision Medicine Awareness
• Growth in Research Partnerships
• Rising AI Innovation Activities

Restraints

• Small Domestic Market
• Limited Genomic Data Availability
• Funding Limitations
• Talent Shortages

Opportunities

• AI-Based Preventive Genomics
• Cross-Border Research Collaborations

Colombia AI In Genomics Market Analysis:

Colombia accounted for approximately 5.20 % of the Latin America market in 2025 and was valued at nearly USD 1.94 Million. Growth is fueled by improving healthcare infrastructure, increasing adoption of genomic testing, expanding digital healthcare programs, and rising government support for innovation in life sciences.

Drivers

• Expansion of Healthcare Innovation Programs
• Increasing Genomic Testing Adoption
• Government Support for Digital Health
• Growth of Research Institutions

Restraints

• Infrastructure Limitations
• Uneven Healthcare Access
• Limited AI Expertise
• Data Quality Challenges

Opportunities

• Precision Medicine Development
• AI-Based Population Health Analytics

Peru AI In Genomics Market Analysis

Peru represented approximately 4.30 % of the Latin America market in 2025 and was valued at around USD 1.61 Million. The country market is driven by healthcare modernization efforts, growing interest in genomics research, increasing disease monitoring initiatives, and expanding adoption of AI-enabled healthcare technologies.

Drivers

• Growing Healthcare Modernization Initiatives
• Rising Interest in Genomics Research
• Expansion of Digital Health Programs
• Increasing Disease Monitoring Efforts

Restraints

• Limited Research Funding
• Shortage of Skilled Professionals
• Low Sequencing Capacity
• Technology Access Barriers

Opportunities

• Genomics Applications in Public Health
• AI-Enabled Disease Risk Prediction

AI in Genomics Market Key Players: Mention share holding of major 5 players

Company	Estimated Market Share (%)
Microsoft Corporation	14.82%
NVIDIA Corporation	13.28%
Deep Genomics	6.42%
Freenome Holdings, Inc.	5.80%
Data4Cure, Inc.	4.17%

AI in Genomics Market Recent Developments

• In December 2025, Gleneagles Hong Kong launched an AI-powered longevity healthcare program integrating genomic and epigenetic testing with physical examinations through Quantum Life's OMICS platform, advancing personalized preventive healthcare and precision medicine services. 
• In November 2025, NVIDIA, Sheba Medical Center, and Icahn School of Medicine at Mount Sinai partnered on a multi-year AI genomics initiative using large language models to analyze underexplored regions of the human genome and accelerate disease research. 
• In July 2025, 10x Genomics and A*STAR Genome Institute of Singapore launched the TISHUMAP project, leveraging AI-powered spatial biology and multimodal data analysis across 2,500 clinical tissue samples to enhance drug target discovery and precision medicine development. 
• In January 2025, Illumina and NVIDIA entered a strategic collaboration to integrate AI with multiomics data analysis, accelerating genomics-based drug discovery, therapeutic development, and advanced clinical research through enhanced sequencing and computational capabilities.. 

AI in Genomics Market Regulatory Landscape Analysis:

• FDA, EMA, PMDA, and NMPA regulatory framework assessment
• AI-enabled medical software and genomics compliance evaluation
• Genomic data privacy and governance analysis (HIPAA, GDPR, and regional regulations)
• Regulatory impact on AI adoption and commercialization strategies

AI in Genomics Market Patent & Intellectual Property Landscape:

• AI-genomics patent filing and innovation trend analysis
• Intellectual property competitiveness assessment
• Licensing agreements and technology transfer evaluation
• Global innovation hubs and patent concentration mapping

AI in Genomics Market Segmentations:

Our research framework strategically segments the AI in genomics market by Component, Technology,Functionality, Application, End Use and key regional markets

By Component

• Software
• Hardware
• Service

By Technology

• Machine Learning (ML)
  • Deep Learning
  • Supervised Learning
  • Unsupervised Learning
  • Others
• Computer Vision

By Functionality

• Genome Sequencing
• Gene Editing
• Others

By Application

• Drug Discovery & Development
• Precision Medicine
• Diagnostics
• Others

By End Use

• Pharmaceutical and Biotech Companies
• Healthcare Providers
• Research Centers
• Others

By Region & Country

North America

• USA
• Canada

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Switzerland
• Netherlands
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Singapore
• Australia
• Thailand
• Malaysia
• Philippines
• Indonesia
• Rest of APAC

Latin America

• Brazil
• Mexico
• Argentina
• Chile
• Colombia
• Peru
• Rest of LA

Middle East & Africa

• Saudi Arabia
• United Arab Emirates
• South Africa
• Egypt
• Israel
• Rest of MEA

Key Report Attributes	Details
Years Considered	2022 to 2035
Market Size 2025	USD 1134.80 Million
Market Size 2035	USD 20558.14 Million
Historical CAGR % (Growth rate)	XX % from 2022 to 2025
Futuristic CAGR % (Growth rate)	33.6% from 2026 to 2035
Segments Covered	· By Component · By Technology · By Functionality · By Application · By End-Use
Regions Covered	· North America · Europe · Asia Pacific · Latin America · Middle East & Africa
Countries Covered	USA; Canada; Germany; United Kingdom; France; Italy; Spain; Switzerland; Netherlands; China; India; Japan; South Korea; Singapore; Australia; Thailand; Malaysia; Philippines; Indonesia; Saudi Arabia; United Arab Emirates; South Africa; Egypt; Israel; Brazil; Mexico; Argentina; Chile; Colombia; Peru
Competitive Landscape Overview	· Microsoft Corporation · NVIDIA Corporation · DEEP GENOMICS · Data4Cure, Inc. · Freenome Holdings, Inc. · Thermo Fisher Scientific · Illumina, Inc. · SOPHiA GENETICS · BenevolentAI · Fabric Genomics
Flexible Report Customization	The study can be customized based on geography, segment analysis, company profiling, competitive benchmarking, and strategic insights.
Data Sources	Primary and secondary sources used (Company filings, trade associations, Journals, Annual report, Publications, Surveys, Investor Presentations, and much more.